Core Insights - Artisan Mid Cap Fund reported strong performance in Q3 2025, with returns of 8.80% for Investor Class and Advisor Class funds, and 8.83% for Institutional Class, significantly outperforming the Russell Midcap Growth Index's 2.78% return [1][2] Company Overview - Veracyte, Inc. (NASDAQ:VCYT) is a diagnostics company specializing in noninvasive cancer tests, with a market capitalization of $2.736 billion as of October 15, 2025 [2][3] - The company achieved a 14% year-over-year revenue growth, totaling $130 million, driven by strong sales of its Decipher® and Afirma® tests [3][4] Product and Market Position - Veracyte's product offerings include three approved tests: Decipher® for prostate cancer, Afirma® for thyroid cancer, and Prosigna® for breast cancer, with ongoing efforts to expand its product line [3] - The company is advancing its Percepta® Nasal Swab test for lung cancer risk assessment and plans to launch a Minimal Residual Disease platform in 2026 [3] Investment Sentiment - Interest in Veracyte among hedge funds increased, with 29 portfolios holding the stock at the end of Q2 2025, up from 24 in the previous quarter [4] - Despite the growth potential of Veracyte, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk [4]